PMID- 18752933 OWN - NLM STAT- MEDLINE DCOM- 20090305 LR - 20151119 IS - 0923-1811 (Print) IS - 0923-1811 (Linking) VI - 53 IP - 1 DP - 2009 Jan TI - Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. PG - 34-9 LID - 10.1016/j.jdermsci.2008.06.008 [doi] AB - BACKGROUND: Anti-cyclic citrullinated peptide antibodies (anti-CCP) are reported to be found in 5-13% of patients with psoriatic arthritis (PsA). However, whether anti-CCP-positive PsA patients and rheumatoid arthritis (RA) patients have a similar pathophysiological background still remains uncertain. OBJECTIVE: To determine the prevalence of anti-CCP antibodies in patients with PsA and characterize these anti-CCP-positive patients of PsA. METHODS: We measured the serum levels of the anti-CCP antibodies in patients with PsA (n=16), psoriasis (n=15), RA (n=9) and healthy controls (n=11). Serum levels of rheumatoid factor (RF), matrix metalloproteinase-3 (MMP-3), cartilage oligomeric matrix protein (COMP), interleukin (IL)-23p19 and IL-12p40 were also measured in all the samples. RESULTS: Two of the 16 PsA patients (13%) were positive for anti-CCP antibodies with high titers of RF. However, the serum IL-23p19 levels were two orders of magnitude higher in the anti-CCP-positive PsA patients as compared with those in the RA patients and anti-CCP-negative PsA patients. No significant elevation of the serum levels of MMP-3, COMP and IL-12p40 was found in these patients. CONCLUSION: Thirteen percent of the PsA patients were positive for anti-CCP. These patients do not fulfill the American College of Rheumatology (ACR) classification criteria for RA so far. Furthermore, they showed the typical clinical features of PsA rather than those of RA. Although anti-CCP-positive PsA patients may possibly be have a risk of developing RA, we propose that these patients be classified, for the moment, into a independent subtype of PsA, as a different entity from RA. FAU - Shibata, Sayaka AU - Shibata S AD - Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. sayakashibata-tky@umin.ac.jp FAU - Tada, Yayoi AU - Tada Y FAU - Komine, Mayumi AU - Komine M FAU - Hattori, Naoko AU - Hattori N FAU - Osame, Satsuki AU - Osame S FAU - Kanda, Naoko AU - Kanda N FAU - Watanabe, Shinichi AU - Watanabe S FAU - Saeki, Hidehisa AU - Saeki H FAU - Tamaki, Kunihiko AU - Tamaki K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080826 PL - Netherlands TA - J Dermatol Sci JT - Journal of dermatological science JID - 9011485 RN - 0 (Antibodies, Anti-Idiotypic) RN - 0 (Biomarkers) RN - 0 (Cartilage Oligomeric Matrix Protein) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Glycoproteins) RN - 0 (Interleukin-12 Subunit p40) RN - 0 (Interleukin-23 Subunit p19) RN - 0 (Matrilin Proteins) RN - 0 (Peptides, Cyclic) RN - 0 (TSP5 protein, human) RN - 0 (cyclic citrullinated peptide) RN - 9009-79-4 (Rheumatoid Factor) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) SB - IM MH - Adult MH - Antibodies, Anti-Idiotypic/*blood MH - Arthritis, Psoriatic/*blood/ethnology/immunology MH - Biomarkers/blood MH - Cartilage Oligomeric Matrix Protein MH - Case-Control Studies MH - Extracellular Matrix Proteins/blood MH - Female MH - Glycoproteins/blood MH - Humans MH - Interleukin-12 Subunit p40/blood MH - Interleukin-23 Subunit p19/*blood MH - Japan MH - Male MH - Matrilin Proteins MH - Matrix Metalloproteinase 3/blood MH - Middle Aged MH - Peptides, Cyclic/*immunology MH - Rheumatoid Factor/blood EDAT- 2008/08/30 09:00 MHDA- 2009/03/06 09:00 CRDT- 2008/08/30 09:00 PHST- 2008/02/19 00:00 [received] PHST- 2008/04/04 00:00 [revised] PHST- 2008/06/25 00:00 [accepted] PHST- 2008/08/30 09:00 [pubmed] PHST- 2009/03/06 09:00 [medline] PHST- 2008/08/30 09:00 [entrez] AID - S0923-1811(08)00201-6 [pii] AID - 10.1016/j.jdermsci.2008.06.008 [doi] PST - ppublish SO - J Dermatol Sci. 2009 Jan;53(1):34-9. doi: 10.1016/j.jdermsci.2008.06.008. Epub 2008 Aug 26.